FGEN - フィブロジェン （FibroGen Inc）

FibroGen (FGEN) stock has been upgraded to buy by Stifel ahead of the expected release of data from two Phase 3 studies for its drug pamrevlumab. Read more here.

Benzinga Pro data, FibroGen (NASDAQ: FGEN ) reported Q1 sales of $36.16 million. Earnings fell to a loss of $76.70 million, resulting in a 15.91% decrease from last quarter. In Q4, FibroGen brought in $34.37 million in sales but lost $66.17 million in earnings. What Is Return On Invested Capital? Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company''s ROIC. A higher ROIC is generally representative of successful growth of a … Full story available on Benzinga.com

LONDON (dpa-AFX) - FibroGen Inc. (FGEN) announced positive data from its Phase 3 clinical study of roxadustat for treatment of anemia in patients receiving concurrent chemotherapy treatment for no…

FibroGen''s (FGEN) oral drug roxadustat was good as recombinant erythropoietin alfa ((SEPO)) in improving hemoglobin level. Read more here

FibroGen, Inc. (NASDAQ:NASDAQ:FGEN) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ETCompany ParticipantsMichael Tung - Vice President, Corporate Strategy & Investor…

This move is a reversal from the hour prior, which saw price move up. The post Fibrogen Inc (FGEN): Price Now Near $14.85; Daily Chart Shows An Uptrend on 50 Day Basis appeared first on ETF Daily News .

Bank of America Corp DE lessened its holdings in shares of FibroGen, Inc. (NASDAQ:FGEN) by 60.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,546 shares of the biopharmaceutical companys stock after selling 163,081 shares during the period. Bank []

FibroGen Inc. (NASDAQ:FGEN) shares, rose in value on Friday, 11/26/21, with the stock price down by -5.66% to the previous days close as strong demand from buyers drove the stock to $12.17. Actively observing the price movement in the last trading, the stock closed the session at $12.90, falling within a range of $12.00 and FibroGen Inc. (NASDAQ: FGEN) Stock Price Forecast: $100 Read More »

UBS Asset Management Americas Inc. reduced its position in shares of FibroGen, Inc. (NASDAQ:FGEN) by 13.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 82,249 shares of the biopharmaceutical companys stock after selling 12,539 shares during the period. UBS Asset []

Global Idiopathic Pulmonary Fibrosis Market Report published by Astute Analytica provides insight and updates about the corresponding segments involved in the global market for the forecast period of 2021-2030. A detailed analysis of the market dynamics is provided and comprehensive

The study examines the global idiopathic pulmonary fibrosis market in detail, including current trends and forecasts, in order to identify potential investment opportunities. Idiopathic pulmonary fibrosis is an interstitial lung disease in which the lung tissues are destroyed, limiting the

Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN ) Alkermes plc (NASDAQ: ALKS ) BeyondSpring Inc. (NASDAQ: BYSI ) ( moved on a co-development and commercialization agreement for chemotherapy-induced neutropenia treatment candidate) BioLife Solutions, Inc. (NASDAQ: BLFS ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) DexCom, Inc. (NASDAQ: DXCM ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Erasca, Inc. (NASDAQ: ERAS ) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) Imago BioSciences, Inc. (NASDAQ: IMGO ) MiMedx Group, Inc. (NASDAQ: MDXG ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Nuvalent, Inc. (NASDAQ: NUVL ) (IPOed July 29) PDS Biotechnology Corporation (NASDAQ: PDSB ) Prothena Corporation plc (NASDAQ: PRTA ) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Repligen Corporation (NASDAQ: RGEN ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 26) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Edgewise Therapeutics, Inc. (NASDAQ: EWTX ) FibroGen, Inc. (NASDAQ: FGEN ) MaxCyte, Inc. (NASDAQ: MXCT ) Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM ) Theravance Biopharma, Inc. (NASDAQ: TBPH ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Stocks In Focus Immutep Announces Award of Chinese Patent For Out-licensed Antibody Treatment Candidate For Cancer and Infectious Disease Immutep Limited (NASDAQ: IMMP ) announced the grant of a patent entitled "Antibody molecules to LAG-3 and uses thereof"

The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN ) and Astellas Pharma''s (OTC: ALPMF ) Evrenzo (roxadustat) for anemia caused by chronic kidney disease (CKD), just days after the FDA turned down the drug. Related: FDA Shoots Down Full story available on Benzinga.com